Group 1 - The core viewpoint of the article emphasizes the policy direction of "supporting true innovation, supporting genuine innovation, and supporting differentiated innovation" in the context of medical insurance for innovative drugs and devices, rejecting pseudo-innovation and inward competition [1] - The meeting covers the entire policy system from research and development, value assessment, medical insurance access to capital support, accelerating the implementation of policies that will further stimulate industry innovation vitality and accelerate industrial upgrading [1] - Companies with independent innovation capabilities are expected to benefit in the long term as the industry evolves towards multi-dimensional development, transitioning from scale expansion to a higher level of development [1] Group 2 - The medical device sector showed strong performance with a July fluctuation of 14.27%, ranking second among six sub-sectors in the pharmaceutical and biological industry [1] - The medical ETF (159828) tracks the CSI Medical Index (399989), which selects representative listed companies in the fields of medical services, medical devices, pharmaceuticals, and biotechnology from the Shanghai and Shenzhen markets [1] - The CSI Medical Index covers multiple sub-industries, including medical equipment, in vitro diagnostics, and high-value consumables, demonstrating strong industry representation [1]